论文部分内容阅读
目的:观察醒脑静注射液治疗重度颅脑损伤的临床效果。方法:重度颅脑损伤患者110例随机分为对照组及观察组每组55例。对照组给予常规基础治疗;观察组在对照组基础上加用醒脑静注射液。两组疗程均为28d。比较两组患者治疗前与治疗1,2,4周后的格拉斯哥昏迷评分(GCS),以及两组患者4周内肺部感染与应激性溃疡发生率,评定4周后两组疾病临床预后效果。结果:治疗2,4周后观察组GCS评分均高于对照组(P<0.05)。两组应激性溃疡发生率无明显差异(P>0.05),但观察组肺部感染发生率明显低于对照组(P<0.05)。观察组临床预后总有效率为90.9%,显著高于对照组的72.7%(P<0.05)。结论:临床重度颅脑损伤患者应用醒脑静注射液联合常规治疗可减少临床并发症,改善患者临床症状,效果显著,值得推广。
Objective: To observe the clinical effect of Xingnaojing injection in treating severe craniocerebral injury. Methods: One hundred and ten patients with severe craniocerebral injury were randomly divided into control group and observation group with 55 cases in each group. The control group was given routine basic treatment; the observation group was added Xingnaojing injection on the basis of the control group. Two groups of treatment are 28d. The Glasgow Coma Scale (GCS) was compared between the two groups before treatment and after treatment for 1, 2, and 4 weeks, and the incidence of pulmonary infection and stress ulcer within 4 weeks in both groups. After 4 weeks, the clinical prognosis effect. Results: GCS scores of the observation group were higher than those of the control group after treatment for 2,4 weeks (P <0.05). There was no significant difference in the incidence of stress ulcer between the two groups (P> 0.05), but the incidence of pulmonary infection in the observation group was significantly lower than that in the control group (P <0.05). The total effective rate of clinical prognosis in observation group was 90.9%, which was significantly higher than that in control group (72.7%, P <0.05). Conclusion: Clinical application of Xingnaojing injection in combination with conventional treatment can reduce the clinical complications and improve the clinical symptoms in patients with severe traumatic brain injury. The results are significant and worthy of promotion.